

## Enrofloxacin/OVA

<b>Cat. No.:</b>	HY-158267
<b>Target:</b>	Antibiotic; Endogenous Metabolite; Bacterial
<b>Pathway:</b>	Anti-infection; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

## Enrofloxacin/OVA

### BIOLOGICAL ACTIVITY

#### Description

Enrofloxacin/OVA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Enrofloxacin (HY-B0502) and OVA. PDCs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases<sup>[1]</sup>.

### REFERENCES

[1]. Fu C, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B. 2023 Feb;13(2):498-516.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA